Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 2
2016 3
2019 1
2020 6
2021 5
2022 5
2023 1
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of transrectal ultrasound-guided tru-cut biopsy as a complementary method for predicting pathological complete response in rectal cancer after neoadjuvant treatment: a phase II prospective and diagnostic trial.
Huang Y, Xie Y, Wang P, Chen Y, Qin S, Li F, Wu Y, Huang M, Hou Z, Cai Y, He X, Lin H, Hu B, Qin Q, Ma T, Tan S, Liao Y, Ke J, Zhang D, Lai S, Jiang Z, Wang H, Xiang J, Cai Z, Wang H, He X, Yang Z, Ren D, Wu X, Hong Y, Huang M, Luo Y, Liu G, Lin J. Huang Y, et al. Among authors: cai y. Int J Surg. 2024 Feb 9. doi: 10.1097/JS9.0000000000001152. Online ahead of print. Int J Surg. 2024. PMID: 38348893
Effects of tumour budding on adjuvant chemotherapy in colorectal cancer.
Xie H, Zeng Z, Hou Y, Ye F, Cai T, Cai Y, Xiong L, Li W, Liu Z, Liang Z, Luo S, Zheng X, Huang L, Liu H, Kang L. Xie H, et al. Among authors: cai y. BJS Open. 2024 Jan 3;8(1):zrad115. doi: 10.1093/bjsopen/zrad115. BJS Open. 2024. PMID: 38190579 Free PMC article.
Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.
Zeng Y, Cai Y, Chai P, Mao Y, Chen Y, Wang L, Zeng K, Zhan Z, Xie Y, Li C, Zhan H, Zhao L, Chen X, Zhu X, Liu Y, Chen M, Song Y, Zhou A. Zeng Y, et al. Among authors: cai y. Front Immunol. 2022 Aug 3;13:961933. doi: 10.3389/fimmu.2022.961933. eCollection 2022. Front Immunol. 2022. PMID: 35990696 Free PMC article.
mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial.
Shen C, Hu H, Cai Y, Ling J, Zhang J, Wu Z, Xie X, Huang M, Wang H, Kang L, Lan P, Wu X, Liu G, Wan Y, Zhou Z, Huang Y, Li F, Wang H, Ma T, Luo S, Cai Y, Shi L, Deng Y. Shen C, et al. Among authors: cai y. Ann Transl Med. 2022 Feb;10(4):171. doi: 10.21037/atm-21-6731. Ann Transl Med. 2022. PMID: 35280386 Free PMC article.
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, Lan P, Wu X, Wang C, Cao W, Hu J, Huang Y, Huang L, Wang H, Shi L, Cai Y, Shen C, Ling J, Xie X, Cai Y, He X, Dou R, Zhou J, Ma T, Zhang X, Luo S, Deng W, Ling L, Liu H, Deng Y. Hu H, et al. Among authors: cai y. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):38-48. doi: 10.1016/S2468-1253(21)00348-4. Epub 2021 Oct 22. Lancet Gastroenterol Hepatol. 2022. PMID: 34688374 Clinical Trial.
24 results